Evidence map›Paper›PMID 31143968›Full record

ArticleClinical neuroradiology2020

What is the Relevance of the Systematic Use of Gadolinium During the MRI Follow-Up of Multiple Sclerosis Patients Under Natalizumab?

Guillaume Bellanger, Damien Biotti, Sofia Patsoura, Jonathan Ciron, Marine Ferrier, Raluca Gramada, Zuzana Meluchova, Fleur Lerebours, Isabelle Catalaa, Hervé Dumas and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical neuroradiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Guillaume BellangerDepartment of Neuroradiology, CHU Purpan, Place du Docteur Baylac, 31059, Toulouse, France. guillaume_bellanger@hotmail.fr.
Damien BiottiDepartment of Neurology, CHU Purpan, Toulouse, France.
Sofia PatsouraDepartment of Neuroradiology, CHU Purpan, Place du Docteur Baylac, 31059, Toulouse, France.
Jonathan CironDepartment of Neurology, CHU Purpan, Toulouse, France.
Marine FerrierDepartment of Neuroradiology, CHU Purpan, Place du Docteur Baylac, 31059, Toulouse, France.
Raluca GramadaDepartment of Neuroradiology, CHU Purpan, Place du Docteur Baylac, 31059, Toulouse, France.
Zuzana MeluchovaDepartment of Neuroradiology, CHU Purpan, Place du Docteur Baylac, 31059, Toulouse, France.
Fleur LereboursDepartment of Neurology, CHU Purpan, Toulouse, France.
Isabelle CatalaaDepartment of Neuroradiology, CHU Purpan, Place du Docteur Baylac, 31059, Toulouse, France.
Hervé DumasDepartment of Neuroradiology, CHU Purpan, Place du Docteur Baylac, 31059, Toulouse, France.
Christophe CognardDepartment of Neuroradiology, CHU Purpan, Place du Docteur Baylac, 31059, Toulouse, France.
David BrassatDepartment of Neurology, CHU Purpan, Toulouse, France.
Fabrice BonnevilleDepartment of Neuroradiology, CHU Purpan, Place du Docteur Baylac, 31059, Toulouse, France.
Hôpital Purpan · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMultiple sclerosis (MS) patients represent a population potentially affected by the intracerebral accumulation of gadolinium-based contrast agents (GBCA) due to repeated magnetic resonance imaging (MRI) performed during their lifetime; however, MRI is still the best tool to monitor MS inflammatory activity.

objectiveThis study aimed to evaluate the relevance of GBCA injections during the MRI follow-up of MS patients under natalizumab (Tysabri) treatment.

methodsThe MRI data results were retrospectively reviewed in a monocentric study (University Hospital of Toulouse, France) from all consecutive patients treated with natalizumab from January 2014 to January 2017. For each examination during the whole MRI follow-up, new lesions (enhancing and non-enhancing) were analyzed.

resultsA total of 129 patients were included in this study (65% female, mean age = 41 years, mean treatment duration 6.5 years, 50% positive for John Cunningham virus) and benefited from 735 MRIs with GBCA. Only 3 MRIs showed a new enhancing lesion, systematically encountered after treatment discontinuation.

conclusionAccording to this study based on the clinical and radiological practice, the systematic use of GBCA seems of limited relevance in the MRI follow-up of asymptomatic patients treated continuously with natalizumab.

Indexed as

Magnetic Resonance ImagingAdultContrast MediaFemaleFranceGadoliniumHumansImmunologic FactorsMaleMiddle AgedMultiple SclerosisNatalizumabRetrospective StudiesContrast MediaGadoliniumImmunologic FactorsNatalizumabDisease activityGadoliniumGadolinium-based contrast agentMagnetic resonance imagingMonitoringMultiple sclerosisTysabri

Identifiers

PMID31143968
OpenAlexW2947503969

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.